CMO to scale up bio anti-cancer drug

Amsterdam-based SynCo Bio Partners has expanded its reach to Japan, where it will manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The contract manufacturer will first consultant with the unnamed drug maker on in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacturing of a live, biotherapeutic-based anticancer drug for Phase I clinical trials. The scale-up effort will include fermentation, formulation and aseptic filling.

SynCo announced a month ago a deal to produce Versartis's lead candidate, a GLP-1 analog for monthly dosing to treat type 2 diabetes. As with the Japanese deal, the CMO is further developing the existing production process. It is also optimizing the manufacturing process to increase yields for cGMP production.

- here's the SynCo release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.